Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

laboratorio farmaco uruguayo, s.a. - carmustina - carmustina....100 mg / etanol deshidratado....3 ml

Malta - English - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - powder and solvent for concentrate for solution for infusion - carmustine 100 mg - antineoplastic agents

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - carmustine - powder and solvent for concentrate for solution for infusion - carmustine

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

clinigen healthcare ltd - carmustine - prolonged-release intralesional implant - 7.7mg

European Union - English - EMA (European Medicines Agency)

medac gesellschaft für klinische spezialpräparate mbh - carmustine - hodgkin disease; lymphoma, non-hodgkin - antineoplastic agents - carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery): , brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases, secondary therapy in non-hodgkin’s lymphoma and hodgkin’s disease, as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (hpct) in malignant haematological diseases (hodgkin’s disease / non-hodgkin’s lymphoma).

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - carmustine, quantity: 100 mg - injection, diluent for - excipient ingredients: ethanol absolute - carmustine-juno is indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in the following: 1. malignant glioma 2. multiple myeloma - in combination with prednisone. 3. hodgkin?s disease - as secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy. 4. non-hodgkin?s lymphomas - as secondary therapy in combination with other approved drugs for patients who relapse while being treated with primary therapy or who fail to respond to primary therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - carmustine, quantity: 100 mg - diluent, not applicable - excipient ingredients: ethanol absolute - carmustine accord is indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in the following:,1. malignant glioma,2. multiple myeloma - in combination with prednisone.,3. hodgkin?s disease - as secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy.,4. non-hodgkin?s lymphomas - as secondary therapy in combination with other approved drugs for patients who relapse while being treated with primary therapy or who fail to respond to primary therapy.